<?xml version="1.0" encoding="UTF-8" ?>
			<?xml-stylesheet href="/rss/rss2html.xsl" type="text/xsl" media="screen"?>
			<rss version="2.0" xmlns:alacra="http://www.alacra.com" xmlns:bir="http://www.alacra.com/bir" xmlns:ccbn="http://www.alacra.com/ccbn" xmlns:newstex="http://www.alacra.com/newstex" ><channel><title>Genzyme Corporation RSS Research Feed - Subscribe Today - AlacraStore.com</title>
<description>Genzyme Corporation</description>
<link>http://www.alacrastore.com/company-snapshot/Genzyme_Corporation-2018845</link>
<lastBuildDate>Saturday, August 30, 2008 12:16:49 AM</lastBuildDate>
<alacra:xlsid>2018845</alacra:xlsid>
<alacra:company>Genzyme Corporation</alacra:company>
<language>en</language>
<generator>AlacraStore RSS Builder 1.0</generator>
<ttl>30</ttl>
<item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0005-27214582</link><guid isPermaLink="false">newstex/PRN-0005-27214582</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> CAMBRIDGE, Mass. and CARLSBAD, Calif., Aug. #, #### (PRNewswire-FirstCall delivered by Newstex) -- Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced that they have begun a phase # study of mipomersen...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016031</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016013</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014009</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07001000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07001005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13001000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13001002</newstex:cat><pubDate>8/6/2008 3:17:54 PM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18018000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18015000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18022000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18020000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19001000</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire US</newstex:Publication><title>Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0005-27214582</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GENZYME CORP</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ISIS PHARMACEUTICALS INC</newstex:index_entry_company><newstex:index_entry_person xmlns:newstex="http://www.alacra.com/newstex">STANLEY T CROOKE</newstex:index_entry_person><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GENZ</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">ISIS</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0005-27205202</link><guid isPermaLink="false">newstex/PRN-0005-27205202</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> SAN DIEGO, Aug. #, #### (PRNewswire delivered by Newstex) -- Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, today announced the addition of a key senior executive to the company's management team.  James...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">09000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">09015000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04006000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04006005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><pubDate>8/6/2008 10:23:42 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18007000</newstex:event><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire US</newstex:Publication><title>Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0005-27205202</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GENZYME CORP</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">LABOPHARM INC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">NEPHROS INC</newstex:index_entry_company><newstex:index_entry_person xmlns:newstex="http://www.alacra.com/newstex">James S Scibetta</newstex:index_entry_person><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">DDS</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">DDSS</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GENZ</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">NEP</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0005-27185961</link><guid isPermaLink="false">newstex/PRN-0005-27185961</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> Aug. #, #### (PR Newswire delivered by Newstex) --     NOVATO, Calif., Aug. # /PRNewswire-FirstCall/ --  Financial Highlights ($ in millions, except per share data)  Item                                     Q# ####        Q# #### Comparison...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">11000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">11009000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">09000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">09015000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016003</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016048</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016018</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016013</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04006000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04006005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">11006000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">11006008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">11006004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><pubDate>8/5/2008 5:21:07 PM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18004000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18008000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18020000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18015000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18022000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18016000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002007</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002008</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19001000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19001032</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire US</newstex:Publication><title>BioMarin Announces Second Quarter 2008 Financial Results</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0005-27185961</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GENZYME CORP</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GENZ</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-26973719</link><guid isPermaLink="false">newstex/BW-0001-26973719</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> Jul. ##, #### (Business Wire) --  Research and Markets (http://www.researchandmarkets.com/research/#a#df#/genzyme_partnering) has announced the addition of the "Genzyme Partnering Guide ####" company profile to their offering.  The...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04018000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016013</newstex:cat><pubDate>7/28/2008 11:21:25 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18015000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18022000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18008000</newstex:event><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><title>Research and Markets: In-depth Insight into the Partnering Interests and Activites of Genzyme</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-26973719</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GENZYME CORP</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GENZ</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/B1833630</link><guid isPermaLink="false">ccbn/B1833630</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>...Debt balance, having the short-term results consistent with putting the building blocks in place for future that Co. is trying to manage in a very active way. ...

</description><pubDate>7/24/2008 6:09:00 AM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Edited</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation Q2 2008 Earnings Conference Call Summary</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">GENZ</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">11:00am ET</ccbn:time><title>Genzyme Corporation Q2 2008 Earnings Conference Call Summary</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Brief</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">B1833630</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T1833630</link><guid isPermaLink="false">ccbn/T1833630</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>...Welcome to the Genzyme Corporation second quarter financial results conference call. All parties will be in a listen-only mode until the question and answer session. (OPERATOR INSTRUCTIONS) I would like to turn the call over to Mr. Patrick Flanigan, Director of Investor Relations. Sir, you may begin. ...

</description><pubDate>7/23/2008 1:06:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation Q2 2008 Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">GENZ</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">11:00am ET</ccbn:time><title>Genzyme Corporation Q2 2008 Earnings Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T1833630</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0005-26863021</link><guid isPermaLink="false">newstex/PRN-0005-26863021</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> CAMBRIDGE, Mass., Jul. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07013000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016018</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016048</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016003</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016013</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016009</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07001000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07001004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><pubDate>7/23/2008 9:18:55 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18020000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18008000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18004000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18023000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18015000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18011000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19001000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002007</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002018</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire US</newstex:Publication><title>Genzyme Reports Strong Second-Quarter Growth</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0005-26863021</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GENZYME CORP</newstex:index_entry_company><newstex:index_entry_person xmlns:newstex="http://www.alacra.com/newstex">HENRI A TERMEER</newstex:index_entry_person><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GENZ</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0005-26730162</link><guid isPermaLink="false">newstex/PRN-0005-26730162</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> CAMBRIDGE, Mass. and SOUTH PLAINFIELD, N.J., Jul. ##, #### (PRNewswire- FirstCall delivered by Newstex) -- Genzyme Corporation (Nasdaq: GENZ) and PTC Therapeutics, Inc. (PTC) today announced an exclusive global collaboration to develop...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07001000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">09000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">09015000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><pubDate>7/17/2008 9:27:05 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18007000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19001000</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire US</newstex:Publication><title>Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0005-26730162</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GENZYME CORP</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PARAMETRIC TECHNOLOGY CORP</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PTC THERAPEUTICS INC.</newstex:index_entry_company><newstex:index_entry_person xmlns:newstex="http://www.alacra.com/newstex">HENRI A TERMEER</newstex:index_entry_person><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GENZ</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PMTC</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PTCT</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/B1879733</link><guid isPermaLink="false">ccbn/B1879733</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>...Isis Pharmaceuticals, Inc. (ISIS) believes the licensing agreement reached with GENZ is one of the most substantial transactions ever for a drug at this stage of development. ...

</description><pubDate>6/24/2008 1:04:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Edited</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation Investor Conference Call Summary</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">GENZ</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">10:00am ET</ccbn:time><title>Genzyme Corporation Investor Conference Call Summary</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Brief</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">B1879733</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T1879733</link><guid isPermaLink="false">ccbn/T1879733</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>...Welcome to the Genzyme investor conference call. (OPERATOR INSTRUCTIONS). Also, this call is being recorded. If you have any objections, you may disconnect at this time. I would like to turn the call over to Mr. Patrick Flanigan, Director of Investor Relations. Sir, you may begin. ...

</description><pubDate>6/24/2008 1:04:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation Investor Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">GENZ</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">10:00am ET</ccbn:time><title>Genzyme Corporation Investor Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T1879733</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0005-26192795</link><guid isPermaLink="false">newstex/PRN-0005-26192795</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> CAMBRIDGE, Mass., and CARLSBAD, Calif., Jun. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced the finalization of the license and collaboration...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07013000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016013</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016048</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014009</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07001000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07001005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13001000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13001002</newstex:cat><pubDate>6/24/2008 9:19:49 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18015000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18008000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18020000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18022000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19001000</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire US</newstex:Publication><title>Genzyme and Isis Complete Licensing of Mipomersen</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0005-26192795</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GENZYME CORP</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ISIS PHARMACEUTICALS INC</newstex:index_entry_company><newstex:index_entry_person xmlns:newstex="http://www.alacra.com/newstex">HENRI A TERMEER</newstex:index_entry_person><newstex:index_entry_person xmlns:newstex="http://www.alacra.com/newstex">STANLEY T CROOKE</newstex:index_entry_person><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GENZ</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">ISIS</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/B1868258</link><guid isPermaLink="false">ccbn/B1868258</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>...Co. reported that CLASSIC-II study data was presented in poster discussion session on ##/##/## at ASCO by one of principal investigators, Harry Erba. ...

</description><pubDate>6/3/2008 2:05:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Edited</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation Conference Call to discuss preliminary data from the CLASSIC-II pivotal study Summary</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">GENZ</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">10:00am ET</ccbn:time><title>Genzyme Corporation Conference Call to discuss preliminary data from the CLASSIC-II pivotal study Summary</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Brief</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">B1868258</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T1868258</link><guid isPermaLink="false">ccbn/T1868258</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>...Welcome to today's conference call. (OPERATOR INSTRUCTIONS). Today's conference is being recorded. If there are any objections, you may disconnect at this time. Now I'll turn the conference over to your host, Katie Forte. You may begin. ...

</description><pubDate>6/3/2008 12:05:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation Conference Call to discuss preliminary data from the CLASSIC-II pivotal study Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">GENZ</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">10:00am ET</ccbn:time><title>Genzyme Corporation Conference Call to discuss preliminary data from the CLASSIC-II pivotal study Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T1868258</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/B1765985</link><guid isPermaLink="false">ccbn/B1765985</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>...Exceeded consensus somewhat and saw very strong performance throughout GENZ and most of the businesses....

</description><pubDate>4/23/2008 1:06:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Edited</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Q1 2008 Genzyme Corporation Earnings Conference Call Summary</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">GENZ</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">11:00am ET</ccbn:time><title>Q1 2008 Genzyme Corporation Earnings Conference Call Summary</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Brief</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">B1765985</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T1765985</link><guid isPermaLink="false">ccbn/T1765985</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>...Welcome to Genzyme Corporations, first quarter financial results conference call. All participants will in a listen-only mode until the question-and-answer session. (OPERATOR INSTRUCTIONS) Please limit your questions to one. Also this call is being recorded. If you have any objections, you may disconnect at this time. I would now like the turn the call over to Mr. Patrick Flanigan, Director of Investor Relations. ...

</description><pubDate>4/23/2008 12:09:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Q1 2008 Genzyme Corporation Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">GENZ</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">11:00am ET</ccbn:time><title>Q1 2008 Genzyme Corporation Earnings Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T1765985</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T1831701</link><guid isPermaLink="false">ccbn/T1831701</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>...Welcome to today's investor conference call. All lines are in a listen-only mode until the question-and-answer session. Today's conference is being recorded. If you have any objections, you may disconnect at this time. I would now like to turn the call over to Mr. Patrick Flanigan, Director of Investor Relations. Sir, you may begin. ...

</description><pubDate>4/21/2008 9:04:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation Provides Update on Myozyme(R) Manufacturing Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">GENZ</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">5:00pm ET</ccbn:time><title>Genzyme Corporation Provides Update on Myozyme(R) Manufacturing Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T1831701</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/B1831701</link><guid isPermaLink="false">ccbn/B1831701</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>...GENZ reported that FDA has asked Co. to file and submit in separate BLA for ####L process because it is LOTS data, www.streetevents.comContact Us ...

</description><pubDate>4/21/2008 8:04:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Edited</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation Provides Update on Myozyme(R) Manufacturing Conference Call Summary</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">GENZ</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">5:00pm ET</ccbn:time><title>Genzyme Corporation Provides Update on Myozyme(R) Manufacturing Conference Call Summary</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Brief</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">B1831701</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/bir/321587</link><guid isPermaLink="false">bir/321587</guid><bir:index_mode xmlns:bir="http://www.alacra.com/bir">norm</bir:index_mode><title>Genzyme Corp.</title><bir:company xmlns:bir="http://www.alacra.com/bir">Genzyme Corp.</bir:company><bir:company xmlns:bir="http://www.alacra.com/bir">Allegro Biologics Div.</bir:company><bir:company xmlns:bir="http://www.alacra.com/bir">FOCAL Inc.</bir:company><bir:company xmlns:bir="http://www.alacra.com/bir">Integrated Genetics Inc.</bir:company><bir:company xmlns:bir="http://www.alacra.com/bir">Sangstat Medical Corp.</bir:company><bir:company xmlns:bir="http://www.alacra.com/bir">Ilex Oncology Inc.</bir:company><bir:cou xmlns:bir="http://www.alacra.com/bir">United States</bir:cou><bir:descr xmlns:bir="http://www.alacra.com/bir">Manufacturing: Biotherapeutics, diagnostic products, pharmaceuticals and fine chemicals. Services: Diagnostic services.</bir:descr><bir:sic xmlns:bir="http://www.alacra.com/bir">2836</bir:sic><bir:ssic xmlns:bir="http://www.alacra.com/bir">3841</bir:ssic><bir:ssic xmlns:bir="http://www.alacra.com/bir">2834</bir:ssic><bir:ssic xmlns:bir="http://www.alacra.com/bir">8071</bir:ssic><bir:naics xmlns:bir="http://www.alacra.com/bir">325414</bir:naics><bir:snaics xmlns:bir="http://www.alacra.com/bir">325412</bir:snaics><bir:snaics xmlns:bir="http://www.alacra.com/bir">339112</bir:snaics><bir:snaics xmlns:bir="http://www.alacra.com/bir">621511</bir:snaics><bir:class xmlns:bir="http://www.alacra.com/bir">17</bir:class><bir:size xmlns:bir="http://www.alacra.com/bir">H</bir:size><bir:revenue xmlns:bir="http://www.alacra.com/bir">K</bir:revenue><bir:ticker xmlns:bir="http://www.alacra.com/bir">GENZ</bir:ticker><pubDate>3/15/2008 6:17:00 AM</pubDate><bir:docid xmlns:bir="http://www.alacra.com/bir">321587</bir:docid><category>Company Profiles &amp; Financials</category><alacra:ip>Gale Company Profiles</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/B1678231</link><guid isPermaLink="false">ccbn/B1678231</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>Q# #### Genzyme Corporation Earnings Conference Call</description><pubDate>2/13/2008 3:53:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Edited</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Q4 2007 Genzyme Corporation Earnings Conference Call Summary</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">GENZ</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">11:00am ET</ccbn:time><title>Q4 2007 Genzyme Corporation Earnings Conference Call Summary</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Brief</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">B1678231</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T1678231</link><guid isPermaLink="false">ccbn/T1678231</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>Q# #### Genzyme Corporation Earnings Conference Call</description><pubDate>2/13/2008 3:53:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Genzyme Corporation</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Q4 2007 Genzyme Corporation Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">GENZ</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">11:00am ET</ccbn:time><title>Q4 2007 Genzyme Corporation Earnings Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T1678231</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item></channel></rss>